-
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies.
More Recent News
-
Leading by Example: A Message of Resilience, Gratitude, and Hope
During a special session at TTLC 2026, Dr. Ross Camidge shared his personal journey with lung cancer, discussing its impact on both his professional and personal life.
-
Personalized Lung Cancer Therapies: One Size Does Not Fit All
During the TTLC 2026 Opening Keynote, Dr. John V. Heymach said personalizing lung cancer therapies will require disentangling heterogeneity to understand the underlying factors driving the disease in each patient.